Form 4: Emergent BioSolutions Executive Trades EBS Stock
Statement of Changes in Beneficial Ownership
Coleen Glessner, EVP at Emergent BioSolutions, reported a transaction involving the withholding of shares to cover taxes related to restricted stock units.
Summary
- Coleen Glessner, Executive Vice President of Quality & Ethics, and CPL at Emergent BioSolutions Inc. (EBS), engaged in a transaction on June 8, 2026.
- This transaction involved the acquisition of 2,018 shares of common stock.
- These shares were withheld to cover taxes associated with the vesting and settlement of restricted stock units.
- Following this transaction, Glessner beneficially owns 202,201 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard tax-related transaction for executive compensation rather than a strategic investment or divestment decision.
Positives
- The transaction indicates the settlement of restricted stock units, which is a common form of executive compensation and can align management interests with shareholders.
- The executive continues to hold a significant number of shares (202,201) directly, suggesting continued beneficial ownership and commitment to the company.
Negatives
- The withholding of shares to cover taxes represents a disposition of equity that could otherwise be held by the executive, potentially reducing their direct stake if not reinvested.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing.
Industry Context
StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions. This specific filing details a common practice of share withholding for tax purposes related to executive compensation, which is standard within the biotechnology and pharmaceutical sectors.
Stakeholder Impact
- Shareholders: The transaction does not represent a sale of shares by the executive, but rather a withholding for tax purposes, thus the direct impact on the executive's ownership stake is minimal and intended to cover tax liabilities.
Key Dates
| Date | Description |
|---|---|
| 06/08/2026 | Transaction Date for the withholding of shares. |
| 06/10/2026 | Date of signature for the filing. |
Keywords
Emergent BioSolutions, EBS, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.